1887

7 : Reemerging Infections: Recent Developments in Pertussis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Reemerging Infections: Recent Developments in Pertussis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816957/9781555811419_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555816957/9781555811419_Chap07-2.gif

Abstract:

Although pertussis (whooping cough) technically qualifies as a reemerging infection by virtue of its increase in reported cases over the last 15 years, there is no doom and gloom about the future of this fascinating illness. Despite the important recent progress summarized in this chapter, there are substantial barriers to overcome in the long-term mission of controlling or eliminating the disease. A variety of primers have been used for pertussis polymerase chain reaction (PCR) assays, and this technology is available in an increasing number of centers. Serology is also being used increasingly to identify patients with pertussis, although this approach is more effective for epidemiologic purposes than in acute diagnosis. This infection is localized to the respiratory tract. Almost certainly, reaches that site via aerosol droplets produced by the cough of an actively infected individual. Immunization with whole cell pertussis vaccine has been the mainstay of public health measures against this illness since the mid-1950s. Future clinical investigation will focus on potential benefit of additional antigens for the acellular vaccines, their duration of protection, and whether they might be used for protection of the adult population which is now recognized as experiencing an increasing incidence of pertussis.

Citation: Hewlett E. 1998. Reemerging Infections: Recent Developments in Pertussis, p 145-158. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch7

Key Concept Ranking

Adenylate Cyclase Toxin
0.5221239
T Helper Cells
0.46741432
Nitric Oxide Synthase
0.4460266
0.5221239
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555816957.chap7
1.Anonymous. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet i:955960.
2.Anonymous. 1991. In C. P. Howson,, C. J. Howe,, and H. V. Fineberg (ed.), Adverse Effects of Pertussis alld Rubella Vaccines. National Academy Press, Washington. D.C..
3.Anonymous. 1991. WHO meeting on case definition of pertussis. World Health Organization. Geneva, Switzerland.
4.Anonymous. 1993. Resurgence of pertussis-United States, 1993. Morbid. Mortal. Weekly Rep. 42:952960.
5.Anonymous. 1994. In K. R. Stratton,, C. J. Howe,, and R. B. Johnston (ed.), DPT Vaccine and Chronic Nervous System Dysfunction: a new Analysis. Nationa1 Academy Press, Washington, D.C..
6.Anonymous. 1997. Proceedings of International Symposium on Pertussis Vaccine Trials. October 30-November I, 1995; Rome, Italy. Dev. Biol. Stand. 89:1410.
7.Anonymous. 1996. Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series. Morbid. Mortal. Weekly Rep. 45:676677.
8.Anonymous. 1997. Pertussis outbreak-Vennont, 1996. Morbid. Mortal. Weekly Rep. 46:822826.
9.Anonymous. 1997. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 46:125.
10. Aoyama, T.,, Y. Takeuchi,, A. Golo,, H. Iwai,, Y. Murase,, and T. Iwata. 1992. Pertussis in adults. Am. J. Dis. Child. 146:163166.
11. Arico, B.,, and R. Rappuoli. 1987. Bordetella parapertussis and Bordetella brollchiseptica contain transcriptionally silent pertussis toxin genes. J. Bacteriol. 169:28472853.
12. Berggard, K.,, E. Johnsson,, F. R. Mooi,, and G. Lindahl. 1997. Bardetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect. lmmun. 65:36383643.
13. Birkebaek, N. H.,, I. Heron,, and K. Skjodt. 1994. Bordetella pertussis diagnosed by polymerase chain reaction. APMIS 102:291294.
14. Black, S. 1997. Epidemiology of pertussis. Pediatr Infect. Dis. J. 16:S8589.
15. Brennan, M. J .,, and R. D. Shahin. 1996. Pertussis antigens that abrogate bacterial adherence and elicit immunity. Am. J. Respir. Crit. Care Med. 154:SI45149.
16. Bromberg, K.,, H. Mendez,, and E. Handelsman. 1995. Chronic infection with B. pertussis (BP) in HIV-infected children. Pediatr. Res. 37:107A. (Abstract 1008.).
17. Bromberg, K.,, G. Tannis,, and P. Steiner. 1991. Detection of Bordelella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect. lmmun. 59:47154719.
18. Cassone, A.,, C. M. Ausi.lIo, F. Urbani, R. Lande, M. Giuliano, A. La Sala, A. Piscitelli, and S. Salmaso. 1997. Cell· mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Arch. Pedialr. Adolesc. Med. 151:283289.
19. Cheers, C.,, and D. F. Gray. 1969. Macrophage behaviour during the complaisant phase of murine pertussis. Immunology 17:875887.
20. Cherry, J. D. 1984. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr. Probl. Pediatr. 14:178.
21. Cherry, J. D. 1997. Comparative efficacy of a cellular pertussis vaccines: an analysis of recent trials. Pediatr. lnfect. Dis. J. 16:S9096.
22. Cherry, J. D.,, L. J. BaralT,, and E. Hewlett. 1989. The past, present, and future of pertussis. The role of adults in epidemiology and future control. West. J. Med. 150:319328.
23. Cherry, J. D.,, P. A. Brunell,, G. S. Golden,, and D. Karzon. 1988. Report of the task force on pertussis and pertussis vaccine. Pediatrics 81:939984.
24. Cimolai, N.,, C. Trombley,, and D. O'Neill. 1996. Diagnosis of whooping cough: a new era with rapid molecular diagnostics. Pediatr. Emerg. Care 12:9193.
25. Confer, D. L.,, and J. W. Eaton. 1982. Phagocyte impotence caused by an invasive bacterial adenylkate cyclase. Science 217:948950.
26. Cookson, B. T.,, A. N. Tyler,, and W. E. Goldman. 1989. Primary structure of the peptidoglycan-derived tracheal cytotox:in of Bordetella pertussis. Biochemistry 28:17441749.
27. Deville, J. G.,, J. D. Cherry,, P. D. Christenson,, E. Pineda,, C. T. Leach,, T. L. KuhIs,, and S. Viker. 1995. Frequency of unrecognized Bordetella pertussis infections in adults. Clin. Infect. Dis. 21:639642.
28. Douglas, E.,, J. G. Coote,, R. Parton,, and W. McPheat. 1993. Identification of Bordetella pertussis in nasopharyngeal swabs by PCR amplification of a region of the adenylate cyclase gene. J. Med. Microbiol. 38: 140144.
29. Edelman, K.,, S. Nikkari,, O. Ruuskanen,, Q. He,, M. Viljanen,, and J. Mertsol, 1996. Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr. Infect. Dis. J. 15:5457.
30. Edwards, K. M. 1993. Acellular pertussis vaccines-a solution to the pertussis problem? J. lnfect. Dis. 168:1520.
31. Ewanowich, C. A.,, A. R. Melton,, A. A. Weiss,, R. K. Sherburne,, and M. S. Peppler. 1989. Invasion of HeLa 229 cells by virulent Bordetella pertussis. lnfect. lmmun. 57:26982704.
32.. Finn, T. M.,, and L. A. Stevens. 1995. Tracheal colonization factor: a Bordetella pertussis secreted virulence determinant. Mol. Microbial. 16:625634.
33. Friedman, R. I.,, K. Nordensson,, L. Wilson,, E. T. Akporiaye,, and D. E. Yocum. 1992. Uptake and intracellular survival of Bordetella pertussis in human macrophages. Infect. Immun. 60:45784585.
34. Glare, E. M.,, J. C. Paton,, R. R. Premier,, A. J. Lawrence,, and I. T. Nisbet. 1990. Analysis of a repetitive DNA sequence from Bordetella pertussis and its application to the diagnosis of pertussis using the polymerase chain reaction. J. Clin. Microbial. 28:19821987.
34.a. Goldman, W. E. Personal communication.
35. Goodwin, M. S.,, and A. A. Weiss. 1990. Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice. Infect. lmmun. 58:34453447.
36. Greco, D.,, S. Salmaso,, P. Mastrantonio,, M. Giuliano,, A. E. Tozzi,, A. Anemona,, M. L. Ciofi degli Atti,, A. Giammanco,, P. Panei,, W. C. Blackwelder,, D. L. Klein,, and S. G. F. Wassilak. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341348.
37. Grimprel, E.,, P. Begue,, I. Anjak,, F. Betson,, and N. Guiso. 1993. Comparison of polymerase chain reaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection. J. Clin. Microbiol. 31:27452750.
38. Gross, R.,, and N. H. Carbonettl. 1993. Differential regulation of Bordetella pertussis virulence factors. Zentralbl Bakteriol. 278:177186.
39. Gustafsson, L.,, H. O. Ha!lander,, P. Olin,, E. Reizenstcin,, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component aceHular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349355.
40. Halperin, S. A.,, and T. J. Marrie. 1991. Pertussis encephalopathy in an adult: case report and review. Rev. Infect. Dis. 13:10431047.
41. He, Q.,, J. Mertsola,, H. Soini,, and M. K. Viljanen. 1994. Sensitive and specific polymerase chain reaction assays for detection of Bordetella pertussis in nasopharyngeal specimens. J. Pediatr. 124:421426.
42. Heiss, L. N.,, J. R. Lancaster, Jr., J. A. Corbett, and W. E. Goldman. 1994. Epithelial autotoxicity of nitric oxide: role in the respiratory cytopathology of pertu ssis. Proc. Natl. Acad. Sci. USA 91:267270.
43. Herwaldt, L. A. 1993. Pertussis and pertussis vaccines in adults. JAMA 269:9394.
44. Hewlett, E. L., 1995. Bordetella species, p. 20782084. In G. L. Mandell,, J. E. Bennett,, and R. Dolin (ed.), Principles and Practices of Infectious Diseases, 4th ed. Churchill Livingstone, New York. N.Y..
45. Hewlett, E. L., 1996. Bordetella pertussis and the central nervous system. p. 655666. In W. M. Scheid,. R. J. Whitley,, and D. T. Durack (ed.). Infections of the Central Nervous System, 2nd ed. Raven Press, New York, N.Y..
46. Hewlett, E. L. 1997. Pertussis: current concepts of pathogenesis and prevention. Pediatr. Infect. Dis. J. 16:57884.
47. Hewlett, E. L. 1997. Preparation and composition of acellular pertussis vaccines. Consideration of potential effects on vaccine efficacy. Dev. Biol. Stand. 89:143151.
48. Hewlett, E. L., New developments in pertussis, p. 112. In G. L. Mandell,, J. E. Bennett,, and R. Dolin (ed.). Principles and Practice of Infectious Diseases Update, vol. 5, no. 2. Churchill Livingstone, New York, N.Y..
49. Hewlett, E. L.,, and J. D. Cherry,. 1997. New and improved vaccines against pertussis, p. 387416. In G. S. Cohon,, J. B. Kaper,, G. C. Woodrow,. and M. M. Levine (ed.), New Generation Vaccines, 2nd ed. Marcel Dekker, Inc., New York. N.Y..
50. Hewlett, E. L., and V. M. Gordon,. 1988. Adenylate cyclase toxin of Bordetella pertussis, p. 193209. In A. C. Wardlaw, and R. Parton (ed.), Pathogenesis and Immunity in Pertussis. John Wiley and Sons, New York, N.Y..
51. Hodder, S. L.,, and E. A. Mortimer, Jr. 1992. Epidemiology of penussis and reactions to pertussis vaccine. Epidemiol. Rev. 14:243267.
52. Hoppe, J. E.,, and C. G. Simon. 1990. In vitro susceptibilities of Bordelella pertussis and Bordetella parapertussis to seven ftuoroquinolones. Antimicrob. Agents Chemother. 34:22872288.
53. Houard, S.,, C. Hackel,, A. Herzog,, and A. Bollen. 1989. Specific identification of Bordetella pertussis by the polymerase chain reaction. Res. Microbial. 140:477487.
54. Kendrick, P. L.,, G. Eldering,, M. K. Dixon,, and J. Misner. 1947. Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route of challenge. Am. J. Public Health 37:803810.
55. Khelef, N.,, C.·M. Bachelet,, B. B. Vargaftig,, and N. Guiso. 1994. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect. Immun. 62:28932900.
56. Khelef, N.,, and N. Guiso. 1995. Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolys is. FEMS Microbial. Lett. 134:2732.
57. Klein, D. L. 1995. Report of the nationwide multicenter acellular pertussis trial. Pediatrics 96:547603.
58. Krantz, I.,, R. Sekura,, B. Trollfors,, J. Taranger,, G. Zackrisson,, T. Lagergard,, R. Schneerson,, and J. Robbins. 1990. Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide. in 18- to 23-month -old children. J. Pediatr. 116:539543.
59. Lewis, K.,, M. A. Saubolle,, F. C. Tenover,, M. F. Rudinsky,, S. D. Barbour,, and J . D. Cherry. 1995. Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis. Pediatr. Infect. Dis. J. 14:388391.
60. Li. Z.,, D. L. Jansen,, T. M. Finn,, S. A. Halperin,, A. Kasina,, S. P. O'Connor,, T. Aoyama,, C. R. Manclark,, and M. J. Brennan. 1994 . Identification of Bordetella pertussis infection by shared-primer PCR. J. Clin. Microbiol. 32:783789.
61. Lichtinghagen, R.,, R. Diedrich-Glaubitz,, and B. von Horsten. 1994. Identification of Borderella pertussis in nasopharyngeal swabs using the polymerase chain reaction: evaluation of detection methods. Eur J. Clin. Chem. Clin. Biochem. 32: 161167.
62. Liese, J. G.,, C. K. Meschievitz,, E. Harzer,, J. Froeschle,, P. Hosbach,, J . E. Hoppe,, F. Porter,, S. Stojanov,, K. Niinivaara,, A. M. Walker,, and B. H. Belohradsky. 1997. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. 16:10381044.
63. Luker, K. E.,, J . L. Collier,, E. W. Kolodziej,, G. R. Marshall,, and W. E. Goldman. 1993. Bordetella pertussis tracheal cytotoxin and other muramyl peptides: distinct structure-activity relationships for respiratory epithelial cytopathology. Proc. Natl. Acad. Sci. USA. 90:23652369.
64. Luker, K. E.,, A. N. Tyler,, G. R. Ma rshall,, and W. E. Goldman. 1995. Tracheal cytotoxin structural requirements for respiratory epithelial damage in pertussis. Mol. Microbiol. 16:733743.
65. Marwick, C. 1996. Acellular pertussis vaccine is licensed for infants. JAMA 276:516518.
66. Meade, B. D.,, and A. Bollen. 1994. Recommendations for use of the polymerase chain reaction in the diagnosis of Bordetella pertussis infections. J. Med. Microbiol. 41:5155.
67. Meade, B. D.,, A. Deforest,, K. M. Edwards,, T. A. Romani,, F. Lynn,, C. H. O'Brien,, C. B. Swartz,, G. F. Reed,, and M. A. Deloria. 1995. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96:570575.
68. Miller, J. F.,, J. J. Mekalanos,, and S. Falkow. 1989. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science 243:916922.
69. Miller, J . J., Jr.,, R. J. Silverberg,, T. M. Saito,, and J. B. Humber. 1943. An agglutinative reaction for Hemophilus pertussis.II. Its relation to clinical immunity. J. Pediatr. 22:644651.
70. Mills, K. H.,, A. Barnard,, J . Watkins,, and K. Redhead. 1993. Cell-mediated immunity to Bordetella pertussis: role of ThI cells in bacterial clearance in a murine respiratory infection model. Infect Immun. 61:399410.
71. Mills, K. H. G.,, M. Ryan,, E. Ryan,, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594602.
72. Mink, C. M.,, J. D. Cherry,, P. Christenson,, K. Lewis,, E. Pineda,, D. Shlian,, J. A. Dawson,, and D. A. Blumberg. 1992. A search for Bordettdla pertussis infection in university students. Clin. Infect. Dis. 14:464471.
73. Mink, C. M.,, C. H. O' Brien,, S. Wassilak,, A. Deforest,, and B. D. Meade. 1994. Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis. Infect. Immun. 62: 11181120.
74. Mink, C. M.,, N. M. Sirota,, and S. Nugent. 1994. Outbreak of pertussis in a fully immunized adolescent and adult population. Arch. Pediatr: Ado/esc. Med. 148:153157.
75. Mortimer, E. A., Jr. 1990. Pertussis and its prevent ion: a family affair. J. Infect. Dis. 161:473479.
76. Nelson, S.,, A. Matlow,, C. McDowell,, M. Roscoe,, M. Karmali,, L. Penn,, and L. Dyster. 1997. Detection of Bordetella pertussis in clinical specimens by PCR and a microtiter plate-based DNA hybridization assay. J. Clin. Microbial. 35: 117120.
77. Nencioni, L.,, G. Volpini,, S. Peppoloni,, M. Bugnoli,, T. DeMagistris,, I. Marsili,, and R. Rappuoli. 1991. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment Infect. Immun. 59:625630.
78. Parton, R. 1996. New perspectives on Bordetella pathogenicity. J. Med. Microbiol. 44:233235.
79. Pearson, R. D.,, P. Symes,, M. Conboy,, A. A. Weiss,, and E. L. Hewlett. 1987. Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin. J. Immunol. 139:27492754.
80. Pittman, M. 1984. The concept of pertussis as a toxin· mediated disease. Pediatr. Infect. Dis. 3:467486.
81. Postels-Multani, S.,, H. J. Schmitt,, C. H. Wirsing von Konig,, H. L. Bock,, and H. Bogaerts. 1995. Symptoms and complications of pertussis in adults. Infection 23:139142.
82. Rappuoli, R. 1994. Pathogenicity mechanisms of Bordetella. Curr. Top. Microbial. Immunol. 192:319336.
83. Rappuoli, R. 1997. Rational design of vaccines. Nat. Med. 3:374376.
84. Redhead, K.,, J. Watkins,, A. Barnard,, and K. H. G. Mills. 1993. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. lmmun. 61:31903198.
85. Reizenstein, E.,, B. Johansson,, L. Mardin,, J. Abens,, R. Mollby,, and H. O. Hallander. 1993. Diagnostic evaluation of polymerase chain reaction discriminative for Bordetella pertussis, B. parapertussis, and B. bronchiseptica. Diagn. Microbiol. lnfect. Dis. 17:185191.
86. Reizenstein, E.,, L. Lindberg,, R. Miillby,, and H. O. Hallander. 1996. Validation of nested Bordetella PCR in pertussis vaccine trial. J. Clin. Microbiol. 34:810815.
87. Ryan, M.,, G. Murphy,, L. Gothefors,, L. Nilsson,, J. Storsaeter,, and K. H. G. Mills. 1997. Bordetella pertussis respiratory infection in children is associated wilh preferential activation of type I T helper cells. J. Infect. Dis. 175:12461250.
88. Sako, W. 1947. Studies on pertussis immunization. J Pediatr. 30:2940.
89. Sato, Y.,, M. Kimura,, and H. Fukumi. 1984. Development of a pertussis component vaccine in Japan. Lancet 1: 122126.
90. Scarlato, V.,, B. Arico,, A. Prugnola,, and R. Rappuoli. 1991. Sequential activation and environmental regulation of virulence genes in Bordetella pertussis. EMBO J. 10:39713975.
91. Sehmitt, H. J.,, C. H. W. von Konig,, A. Neiss,, H. Bogaerts,, H. L. Bock,, H. Sehulte-Wissermann,, M. Gahr,, R. Sehult,, J. U. Folkens,, W. Rauh,, and R. Clemens. 1996. Efficacy of acellular pertuss is vaccine in early childhood after household exposure. JAMA 275:3741.
92. Shvartzman, P.,, R. Mader,, and T. Stopler. 1989. Hemiated lumbar disc associated with pertussis. J. Fam. Pract. 28:224225.
93. Simondon, F.,, M. P. Preziosi,, A. Yam,, C. T. Kane,, L. Chabirand,, I. Iteman,, G. Sanden,, S. Mboup,, A. HolTenbach,, K. Knudsen,, N. Guiso,, S. Wassilak,, and M. Cadoz. 1997. A random· ized double-blind trial comparing a two·component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15:16061612.
94. Smith, S.,, and R. C. Tilton. 1996. Acute Bordetella pertussis infection in an adult. J. Clin. Microbiol. 34:429430.
95. Stehr, K.,, J. D. Cherry,, U. Heininger,, S. Schmitt-Grobe,, M. Uberall,, S. Laussucq,, T. Eckhardt,, M. Meyer,, R. Engelhardt,, and P. Christenson. 1998. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics. 101:111.
96. Storsaeter, J.,, H. Hallander,, C. P. Farrington,, P. Olin,, R. Miillby,, and E. Miller. 1990. Sec· ondary analyses of the efficacy of two acellular pertuss is vaccines evaluated in a Swedish phase III trial. Vaccine 8:457461.
97. Trollfors, B.,, J. Taranger,, T. Lagergard,, L. Lind,, V. Sundh,, G. Zackrisson,, C. Lowe,, W. Blackwelder,, and J. B. Robbins. 1995. A placebo·controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333: 10451050.
98. Thomanen, E., 1988. Bordetella pertussis adhesins, p. 7594. In A. C. Wardlaw, and R. Parton (ed.), Pathogenesis and Immunity in Pertussis. John Wiley and Sons, Inc.. New York, N.Y..
99. Tuomanen, E.,, and A. Weiss. 1985. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory·epithelial cells. J. Infect. Dis. 152:118125.
100. Ui, M., 1988. The multiple biological activities of pertussis toxin. p. 121146. In A. C. Wardlaw, and R. Parton (ed.), Pathogenesis and Immunity in Pertussis. John Wiley and Sons, Inc. New York. N.Y..
101. Ui, M., 1990. Pertussis toxin as a valuable probe for G-protein involvement in signal transduction, p. 4578. In J. Moss, and M. Vaughan (ed.). ADP-Ribosylating Toxins and G Proteins. American Society for Microbiology, Washington. D.C..
102. Wadowsky, R. M.,, R. H. Michaels,, T. Libert,, L. A. Kingsley,, and G. D. Ehrlich. 1996. Multiplex PCR-based assay for detection of Bordetella pertussis in nasopharyngeal swab specimens. J. Clin. Microbial. 34:26452649.
103. Weiss, A. A.,, E. L. Hewlett,, G. A. Myers,, and S. Falkow. 1983. Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect. Immun. 42:334l.
104. Wilson, R.,, R. Read,, M. Thomas,, A. Rutman,, K. Harrison,, V. Lund,, B. Cookson,, W. Goldman,, H. Lambert,, and P. Cole. 1991. Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro. Infect. Immun. 59:337345.
105. Wright, S. W.,, K. M. Edwards,, M. D. Decker,, and M. H. Zeldin. 1995. Pertussis infection in adults with persistent cough. JAMA 273:10441046.

Tables

Generic image for table
Table 1

Virulence factors of

Citation: Hewlett E. 1998. Reemerging Infections: Recent Developments in Pertussis, p 145-158. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch7
Generic image for table
Table 2

Results from seven acellular pertussis vaccine trials

Citation: Hewlett E. 1998. Reemerging Infections: Recent Developments in Pertussis, p 145-158. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch7

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error